TY - JOUR
T1 - Single institution experience with recombinant gamma-interferon in the treatment of patients with metastatic renal cell carcinoma
AU - Mani, Sridhar
AU - Poo, Wen Jen
PY - 1996/4
Y1 - 1996/4
N2 - We report the clinical course of eight patients with metastatic renal cell carcinoma (RCC) who were treated with recombinant gamma-interferon (Immuneron) as part of a phase II-III study comparing the safety and efficacy of gamma-interferon with that of medroxyprogesterone acetate (Depo-Provera). There were no objective responders among the eight patients treated with recombinant gamma-interferon at an i.v. dose of 1 mg/m2 daily for five days every other week for four weeks then 1 mg/m2 three times a week given every other week until there was documented disease progression or complete response (CR). Overall median survival was 17.3 months (range 1.4 to 184). The major side effects of treatment included fever/chills (75%), mild anorexia and fatigue (75%), nausea/vomiting (80%), leukopenia (38%), and abnormal liver function tests (25%). There were no life-threatening side effects observed. At our institution, in a random cohort of eight patients with metastatic RCC, recombinant gamma-interferon when given at a dose of 1 mg/m2 per day given three times per week on an every other week schedule yields no clinical antitumor activity. A review of the literature on the use of gamma-interferon for metastatic RCC suggests that low-dose combination therapy with other cytokines may yield the best response-to-side effect ratio. Higher doses yield more responses but at an added cost of more toxicity.
AB - We report the clinical course of eight patients with metastatic renal cell carcinoma (RCC) who were treated with recombinant gamma-interferon (Immuneron) as part of a phase II-III study comparing the safety and efficacy of gamma-interferon with that of medroxyprogesterone acetate (Depo-Provera). There were no objective responders among the eight patients treated with recombinant gamma-interferon at an i.v. dose of 1 mg/m2 daily for five days every other week for four weeks then 1 mg/m2 three times a week given every other week until there was documented disease progression or complete response (CR). Overall median survival was 17.3 months (range 1.4 to 184). The major side effects of treatment included fever/chills (75%), mild anorexia and fatigue (75%), nausea/vomiting (80%), leukopenia (38%), and abnormal liver function tests (25%). There were no life-threatening side effects observed. At our institution, in a random cohort of eight patients with metastatic RCC, recombinant gamma-interferon when given at a dose of 1 mg/m2 per day given three times per week on an every other week schedule yields no clinical antitumor activity. A review of the literature on the use of gamma-interferon for metastatic RCC suggests that low-dose combination therapy with other cytokines may yield the best response-to-side effect ratio. Higher doses yield more responses but at an added cost of more toxicity.
KW - Biologic response modifier
KW - Gamma-interferon
KW - Renal cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=0029873399&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029873399&partnerID=8YFLogxK
U2 - 10.1097/00000421-199604000-00012
DO - 10.1097/00000421-199604000-00012
M3 - Article
C2 - 8610639
AN - SCOPUS:0029873399
SN - 0277-3732
VL - 19
SP - 149
EP - 153
JO - American Journal of Clinical Oncology: Cancer Clinical Trials
JF - American Journal of Clinical Oncology: Cancer Clinical Trials
IS - 2
ER -